Back to top
more

Ionis Pharmaceuticals, Inc. (IONS)

(Delayed Data from NSDQ)

$62.54 USD

62.54
710,214

+1.51 (2.47%)

Updated Jan 20, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (188 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for IONS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Ionis Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Assets          
Cash & Equivalents NA 2,500 2,084 1,023 668
Receivables NA 63 13 63 108
Notes Receivable NA 0 0 0 0
Inventories NA 18 9 10 7
Other Current Assets NA 140 102 72 15
Total Current Assets NA 2,721 2,208 1,168 798
Net Property & Equipment NA 154 132 122 93
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 306 291 0 0
Intangibles NA 26 24 22 20
Deposits & Other Assets NA 28 13 10 1
Total Assets NA 3,233 2,668 1,322 912
Liabilities & Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Notes Payable NA 0 0 0 0
Accounts Payable NA 16 29 25 21
Current Portion Long-Term Debt NA 2 14 2 1
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 104 78 92 60
Income Taxes Payable NA 33 0 0 0
Other Current Liabilities NA 118 160 106 51
Total Current Liabilities NA 273 280 225 134
Mortgages NA 60 60 60 0
Deferred Taxes/Income NA 490 567 73 15
Convertible Debt NA 710 568 533 501
Long-Term Debt NA 16 5 13 91
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0 72
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,549 1,481 903 813
Shareholders Equity 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,204 2,047 1,550 1,311
Retained Earnings NA -708 -967 -1,187 -1,181
Other Equity NA 188 107 56 -30
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,685 1,187 419 100
Total Liabilities & Shareholder's Equity NA 3,233 2,668 1,322 912
Total Common Equity 0 1,685 1,187 419 100
Shares Outstanding 139.80 140.60 137.50 124.80 121.20
Book Value Per Share 0.00 11.98 8.63 3.36 0.82

Fiscal Year End for Ionis Pharmaceuticals, Inc. falls in the month of December.

All items in Millions except Per Share data.

12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Assets          
Cash & Equivalents NA 2,329 2,349 2,384 2,500
Receivables NA 39 28 29 63
Notes Receivable NA 0 0 0 0
Inventories NA 22 24 23 18
Other Current Assets NA 147 131 122 140
Total Current Assets NA 2,537 2,531 2,558 2,721
Net Property & Equipment NA 182 173 164 154
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 308 306 310 306
Intangibles NA 28 28 27 26
Deposits & Other Assets NA 41 41 33 28
Total Assets NA 3,096 3,079 3,091 3,233
Liabilities & Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 16 7 21 16
Current Portion Long-Term Debt NA 6 5 4 2
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 109 91 79 104
Income Taxes Payable NA 9 28 33 33
Other Current Liabilities NA 104 100 121 118
Total Current Liabilities NA 245 231 258 273
Mortgages NA 60 60 60 60
Deferred Taxes/Income NA 430 449 468 490
Convertible Debt NA 739 729 720 710
Long-Term Debt NA 16 15 15 16
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,489 1,484 1,521 1,549
Shareholders Equity 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 2,312 2,272 2,234 2,204
Retained Earnings NA -909 -878 -846 -708
Other Equity NA 204 201 183 188
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 1,606 1,595 1,570 1,685
Total Liabilities & Shareholder's Equity NA 3,096 3,079 3,091 3,233
Total Common Equity 0 1,606 1,595 1,570 1,685
Shares Outstanding 139.80 139.80 139.70 139.30 140.60
Book Value Per Share 0.00 11.49 11.42 11.27 11.98